Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.
Here are some examples of why “soft skills,” such as those related to relationship building, leadership, and communication, are essential to today’s pharma and biotech leaders.
Companies frequently talk about being patient-centric. But what I don’t hear discussed as often is the role of the patient after a drug is approved. And I am convinced it is equally important. Why? Because patients are not static; they grow and change over time.
Aside from the clinical opportunity that gene therapy products present; they do introduce tremendous complexity into both the manufacturing and commercial processes. Remember these three points before developing your gene therapy plan.
While the costs and reputational implications associated with pharma data breaches are enough to pay heed to cybersecurity, these compromises can pose a serious threat to patient safety.
Similar to a clinical trial setback, misclassification of independent contractors (ICs) can have a substantial negative impact on a pharma business.
Pharma companies that don’t emphasize risk management and insurance due diligence while adding exposures from new products or services to their policies will see the far-reaching impacts on their budgets.
New research confirms that many of the challenges sponsors face managing clinical trials stem from the disparate nature of processes and systems.
Much has been written about opportunities for improving the drug development process. Although there are many areas ripe for process improvements, let’s focus on the following five.
Many parents can tell a story about the lengths they’ve gone to help their children when no doctor could provide an answer. But there’s one story that stands out to me above the rest because it really drives home the vital need for data sharing, digital collaboration, and the establishment of a connected health ecosystem in the life sciences industry.
Often when we think about inefficiencies in the clinical trial process, we focus on the role of the sponsor or CRO, a particular aspect of the value chain, or new technologies that promote data sharing and faster decision making. While these are critical aspects that drive day-to-day operations, there is another aspect of the value chain that we may be neglecting: the patient side.
Rob Wright shares a personal anecdote about his experience of breaking into the biopharmaceutical industry, along with insight from three biopharma CEOs on what can be done to save the industry’s
Liz Barrett, CEO of Novartis Oncology, discusses taking a proactive approach toward mentoring tomorrow’s leaders.
Novartis Oncology CEO, Liz Barrett, on career advancement and family, a common challenge for women in the workplace.
Rob Wright shares what makes the CNS Summit the best conference he has ever attended.
What sets the Netherlands biopharma sector apart from the rest of the world? That’s what Chief Editor Rob Wright hoped to find out as he began his press tour of the country’s biopharma industry.